

Gebremedhn et al., Supplemental TABLE S1: FOXO1-SiRNA and NC-siRNA constructs used in the present study.

siRNA construct	Sequence (5' - 3')
FOXO1-siRNA	5'-GCC AAG TCT GAC GAA A-3' 5'-CCG CAC GAC TTG AAA A-3'
NC-siRNA	5'-AAC ACG TCT ATA CGC-3'

Gebremedhn et al., Supplemental TABLE S2: List of primers used in this study.

Gene	Primer Sequence (5'-3')	Tm(°C)	Usage	Accession No.
<i>FOXO1</i>	F:AAGAGCGTGCCCTACTTCAA R:CTCTTCTCCTGGGGGATTTC	57	qPCR	XM_583090
<i>FASL</i>	F:AAGAGGAGGGACCACAACA R:TGGGGTGACCTATTTGCTTC	55	qPCR	NM_001098859
<i>FSHR</i>	F:GCAGTCGAACTGAGGTTTGT R:AGATATCGGAGGTTGGGAAG	57	PCR	XM_002700755
<i>LHR</i>	F:AAACATGCCATTCCAGTCAT R:GGACTGCCATTTTCTTAGCA	57	PCR	NM_174381
<i>PTX3</i>	F:ACCTGGGATTCAAAGAAAGG R:CACCCTCCCAGATATTGAAG	56	qPCR	XM_614753
<i>PTGS2</i>	F:CGATGAGCAGTTGTTCCAGA R:GAAAGACGTCAGGCAGAAGG	55	qPCR	NM_174445
<i>GAPDH</i>	F:AATGGAGCCATCACCATC R:GTGGTTCACGCCCATCACA	55	PCR, qPCR	NM_001034034

Gebremedhn et al., Supplemental TABLE S3: Cell cycle distribution of granulosa cells transfected with miR-183~96~182 Cluster miRNAs inhibitors.

Product	G0/G1 (%)	S (%)	G2/M (%)
miR-183-Inh	73.92 ±0.52	12.14 ±0.77	13.94 ±1.28
miR-96-Inh	72.20 ±0.78	13.56 ±0.36	14.23 ±1.15
miR-182-Inh	72.91 ±0.26	12.97 ±0.52	14.11 ±0.78
Pool-Inh	72.56 ±0.86	13.27 ±1.08	14.17 ±0.28
NC-Inh	73.74 ±0.99	11.89 ±0.63	14.38 ±1.47